Clinical trials: Dementia of Alzheimer Type
Alzheimer's Disease
A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia
This is a Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients with Alzheimer's Disease Type Dementia.
- Trial name
- NCT02185053
- Testing
- CPC-201
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Gut Microbiota, Mild Cognitive Impairment
Intervention of Intestinal Microorganism in Mild Cognitive Impairment
Alzheimer's disease (AD) is the most common form of neurodegenerative disorders leading to dementia. Currently, there has been no effective drugs targeting this disease.
- Conditions
- Gut Microbiota, Mild Cognitive Impairment, Dementia, Alzheimer Type, Neuroimaging
- Trial name
- NCT03991195
- Testing
- Probiotic supplemented intervention
- Where
- China
- Volunteers
- 90 people
- Sponsor
- XuanwuH 2
Alzheimer Disease 3, Epilepsy
Improvement Effect of Lacosamide and Levetiracetam on Cognitive in Alzheimer's Disease Patients With Epilepsy
Participants will perform Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating (CDR), Alzheimer's disease assessment scale-cognitive section (ADAS-Cog), Hamilton Anxiety Scale…
- Trial name
- NCT05969054
- Testing
- Lacosamide 100 mg, Levetiracetam 250mg
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Xiangya Hospital of Central South University
Pre Diabetes
Assessment of the Impact of a Personalised Nutrition Intervention in Impaired Glucose Regulation
This study will determine if DNA-based dietary guidelines can improve glucose regulation in pre-diabetic individuals significantly more than standard dietary guidelines following 6 weeks of the intervention.
- Trial name
- ASPIRE-DNA (NCT03702465)
- Testing
- DNA-based dietary intervention, DNA-based dietary intervention using an app, Control arm
- Where
- United Kingdom
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Alzheimer Disease
Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers
This is a Phase 1, randomized, double-blind, placebo-controlled, 6-period crossover study to evaluate the effects of BPN14770 10 mg and 50 mg in reversing scopolamine-induced cognitive impairment in healthy volunteers.
- Trial name
- NCT03030105
- Testing
- BPN14770, Donepezil, Scopolamine 0.6 MG/ML
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Tetra Discovery Partners
Alzheimer Disease
A Clinical Trial to Evaluate the Initial Safety and Efficacy of Repetitive BBB (Blood Brain Barrier) Disruption Using High Intensity Focused Ultrasound 'ExAblate 4000 Type 2.1' in Patients With Alzheimer's Disease
This clinical trial is designed to evaluate the initial safety and efficacy of opening the blood brain barrier (BBB) in patients with Alzheimer's disease using the ExAblate 4000 Type 2.1, a MR guided high-intensity focused…
- Trial name
- NCT06474013
- Testing
- ExAblate 4000 Type 2.1
- Volunteers
- 15 people
- Sponsor
- Korea University Anam Hospital
Neurodegenerative Diseases, Dementia
Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis
This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network.
- Trial name
- NAVAIDD (NCT06339190)
- Testing
- Venepuncture
- Where
- 2 sites in Australia
- Volunteers
- 1,000 people
- Sponsor
- Monash University
Alzheimer Disease, Dementia
Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
This is a multinational, randomized, double blind, placebo controlled, parallel group study comparing the safety and efficacy of daily dosing of 800 mg twice daily MPC-7869 to placebo.
- Trial name
- NCT00322036
- Testing
- MPC-7869
- Where
- 92 sites in United States, Belgium and 10 more
- Volunteers
- 800 people
- Sponsor
- Myrexis Inc.
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Alzheimer Disease, Dementia, Mild
Event-Related Potential (ERP) Components in Clinical Diagnosis
In this study, the investigators will use a novel electroencephalogram (EEG) system that participants will wear during a single in-person research session to investigate whether ERPs are now ready for validation as a tool…
- Conditions
- Alzheimer Disease, Dementia, Mild, Mild Cognitive Impairment
- Trial name
- NCT05673759
- Testing
- Electroencephalogram (EEG) system, Standard Neuropsychological Testing, Additional neuropsychological tests
- Where
- United States
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Boston University
Alzheimer's Type Dementia
Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
The purpose of this study is to compare 23 mg donepezil sustained release to the currently marketed formulation of 10 mg donepezil immediate release in patients with severe Alzheimer's disease.
- Trial name
- NCT01539031
- Testing
- E2020
- Where
- 54 sites in Japan
- Volunteers
- 351 people
- Sponsor
- Eisai Co., Ltd.
Dementia, Dementia, Mild
Chocolate and Physical Exercise to Reduce Malnutrition in Pre-dementia Aged People
We hypothesize that the antioxidant and cytoprotective functions of vitamin E combined with the cortisol-lowering effect of chocolate polyphenols and physical activity may help prevent the age-dependent decline of mitochondrial…
- Conditions
- Dementia, Dementia, Mild, Dementia Moderate, Dementia Senile
- Trial name
- Choko-AGE (NCT05343611)
- Testing
- Combination of High Protein Diet and Physical Exercise protocol, HPP Choko, HPP/VE Choko
- Where
- 4 sites in Italy
- Volunteers
- 102 people
- Sponsor
- Massimo Venturelli, PhD
Dementia, Alzheimer Type
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease.
- Trial name
- XanADu (NCT02727699)
- Testing
- Xanamem™
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 185 people
- Sponsor
- Actinogen Medical
Dementia, Alzheimer Type
Memantine Versus Donepezil in Early Stages of Alzheimer's Disease
It is well known that in the brain of the patients with Alzheimer's disease there is a glutamatergic hyperstimulation leading to neuronal death. Memantine is a low affinity antagonist of NMDA glutamate receptors.
- Trial name
- NCT00505167
- Testing
- Memantine, Donepezil
- Where
- 3 sites in Spain
- Volunteers
- 64 people
- Sponsor
- Hospital Miguel Servet
Agitation in Patients With Dementia of the Alzheimer's Type
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
This study was conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with…
- Trial name
- NCT04408755
- Testing
- AVP-786
- Where
- 95 sites in United States, Bulgaria and 9 more
- Volunteers
- 184 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer's Disease
An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of two fixed doses (16mg/day and 24mg/day) of galantamine (a drug for treating dementia) versus placebo for the treatment of patients with Alzheimer's disease.
- Trial name
- NCT00814801
- Testing
- Galantamine 16 mg/day, Galantamine 24 mg/day
- Where
- Japan
- Volunteers
- 580 people
- Sponsor
- Janssen Pharmaceutical K.K.
Monoclonal B-Cell Lymphocytosis, Chronic Lymphocytic Leukemia
Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)
The aim of this proposal is to identify immune biomarkers, genetic risk, and the clinical consequences of low count monoclonal B-cell lymphocytosis (LC MBL), a common premalignant condition affecting up to 17% of European adults…
- Conditions
- Monoclonal B-Cell Lymphocytosis, Chronic Lymphocytic Leukemia, Infections, Cancers
- Trial name
- MBL RiskConseq (NCT06416267)
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Haifa
Dementia of Alzheimer Type, Dementia Frontotemporal
Multifactorial Approach to Dementia, Multicentric Study
The goal of this observational study is to assess the role of narcisistic personality disorder and life stressful events in conversion rate to dementia, using a three tier approach along three research lines employing subjects…
- Conditions
- Dementia of Alzheimer Type, Dementia Frontotemporal, Narcissistic Personality Disorder, Depression
- Trial name
- NCT05923307
- Where
- Argentina
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Daniel Serrani Azcurra
Alzheimer Disease
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.
- Trial name
- NCT00041678
- Testing
- aripiprazole
- Where
- 6 sites in United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
AL Amyloidosis
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
This is a global, multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered intravenously in adults with AL amyloidosis who…
- Trial name
- PRONTO (NCT02632786)
- Testing
- NEOD001
- Where
- 40 sites in United States, Australia and 8 more
- Volunteers
- 129 people
- Sponsor
- Prothena Biosciences Ltd.